A Phase 3 interventional study of Genotonorm (Somatropin) in Fetal Growth Retardation, sponsored by Pfizer. Completed at 22 sites in France. Open to participants aged 4 Years to 9 Years. Per ClinicalTrials.gov, last updated 2010-06-15.
Sponsored by Pfizer · Phase 3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 29 studies in Fetal Growth Retardation with a site in France — 8 open to participants now, 8 under way, 2 of them phase 3. Fetal Growth Retardation · France.
Among the 29 studies in Fetal Growth Retardation with a site in France, this one is the 15th largest by enrollment of the 16 interventional ones that give a count, is the only one that started in 2005, is one of 7 in phase 3, and was the 1st registered.
262 studies on the registry are indexed under Fetal Growth Retardation; 69 are open to participants now.
Browse Fetal Growth Retardation studies →8 of the 29 studies in Fetal Growth Retardation with a site in France are open now. Recruiting first, the newest first:
University Hospital, Strasbourg, France · Sites in France
Ages 18+ · Women only
Institut National de la Santé Et de la Recherche Médicale, France · Sites in France
Ages up to 5 mo · Healthy volunteers
Centre Hospitalier Universitaire de Nīmes · Sites in France
Ages 18+ · Women only
Central Hospital, Nancy, France · Sites in France
Ages 18–64 · Women only
University Hospital, Bordeaux · Sites in France
Ages 18+ · Women only
A study can be open while its sites in France have not opened yet or have stopped. Only those recruiting at a site in France →
Of the 48 Fetal Growth Retardation studies recruiting now, 24 (50%) set no upper age limit and 21 (44%) stop at 75 or younger; 16 take children under 18; 24 take healthy volunteers.
This study: 4 Years to 9 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
29 studies; the count open now beside each. This study's row is marked.
First in 1993; this study’s year is marked. 1 started in 2005.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 57 is below the median of 150 across 110 interventional studies indexed under Fetal Growth Retardation.
Median enrollment 207 across the 16 interventional studies, 220 across the 13 observational. Of the 16 that completed or were terminated, 2 (13%) have results posted.
This tab as a report to print or save as PDF → With an account.
3 of 29 have an industry lead sponsor. The 10 most frequent:
Pfizer is the lead sponsor of 3,337 studies on the registry; 146 are open to participants now.
Of its 601 completed or terminated interventional studies of FDA-regulated products, 392 (65%) have results posted.
Pfizer has 2 studies filed under Fetal Growth Retardation — fewer than ten, so there is no comparison to draw.
2 of the studies in Fetal Growth Retardation with a site in France that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT05674487University Hospital, BordeauxProstaglandins Versus Trans-cervical Balloon for Induction of Labor in Fetal Growth Restriction (PROBIN) | 2026-12-01 |
| NCT07864272University Hospital, Strasbourg, FranceAssessment of Invasive Genetic Testing in Fetuses With Isolated Intrauterine Growth Restriction Diagnosed After 28 Weeks of Gestation at Strasbourg University Hospitals (2016-2023) | 2026-12-12 |
Add all 2 to your calendar (.ics) → With an account.
Among the 29 studies in Fetal Growth Retardation with a site in France, from their registry updates:
This tab as a report to print or save as PDF → With an account.
To estimate the percentage of children with serum IGF-1 > 2 standard deviation (compared to a child of the same gender and age and without growth hormone (GH) deficiency) 9 months and 12 months after initiation of GH treatment.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Drug: Genotonorm (Somatropin)
0.40 mg/kg/week dived in 7 daily subcutaneous injections during 2 years
Percentage of Children With Insulin Growth Factor-1 (IGF-1) > 2 Standard Deviation (SD) at 9 and 12 Months
Percentage of children with serum IGF-1 \> 2 SD (compared to a child of the same gender and age and without growth hormone (GH) deficiency) 9 months and 12 months after initiation of GH treatment. 9 months and 12 months are combined.
Time frame: 9 and 12 months
Change in Height SD Chronological Age (CA) From Baseline at 12 Months in Children With IGF-1 < = 2 SD at 9 or 12 Months
The height in SD was calculated using Sempe reference means and standard deviations for height. Change in height SD was calculated as height in SD at "12 months" minus height in SD at "Baseline".
Time frame: Baseline, 12 months
Change in Height SD CA From Baseline at 24 Months in Children With IGF-1 < = 2 SD at 9 or 12 Months
The height in SD was calculated using Sempe reference means and SDs for height. Change in height SD was calculated as height in SD at "24 months" minus height in SD at "Baseline".
Time frame: Baseline, 24 months
Change in Height SD CA From Baseline at 12 and 24 Months in Children With IGF-1 > 2 SD at 9 and 12 Months
The height in SD was calculated using Sempe reference means and SDs for height. Change in height SD was calculated as height in SD at "12 or 24 months" minus height in SD at "Baseline".
Time frame: Baseline, 12 and 24 months
Change in Height SD Bone Age (BA) From Baseline at 12 Months in Children With IGF-1 < = 2 SD at 9 or 12 Months
The height in SD was calculated using Sempe reference means and SDs for height. Change in height SD was calculated as height in SD at "12 months" minus height in SD at "Baseline".
Time frame: Baseline, 12 months
Change in Height SD BA From Baseline at 24 Months in Children With IGF-1 < = 2 SD at 9 or 12 Months
The height in SD was calculated using Sempe reference means and SDs for height. Change in height SD was calculated as height in SD at "24 months" minus height in SD at "Baseline".
Time frame: Baseline, 24 months
Change in Height SD BA From Baseline at 12 and 24 Months in Children With IGF-1 > 2 SD at 9 and 12 Months
The height in SD was calculated using Sempe reference means and SDs for height. Change in height SD was calculated as height in SD at "12 or 24 months" minus height in SD at "Baseline".
Time frame: Baseline, 12 and 24 months
Summary of Growth Rate SD (CA) at 12 and 24 Months in Children With IGF-1 < = 2 SD at 9 or 12 Months
Growth rate SD CA at 12 months was calculated as:(Growth rate at 12 months minus reference mean for CA at 12 months) divided by reference SD for CA at 12 months Growth rate SD CA at 24 months was calculated as:(Growth rate at 24 months minus reference mean for CA at 24 months) divided by reference SD for CA at 24 months
Time frame: 12 and 24 months
Summary of Growth Rate SD (CA) at 12 and 24 Months in Children With IGF-1 > 2 SD at 9 and 12 Months
Growth rate SD CA at 12 months was calculated as: (Growth rate at 12 months minus reference mean for CA at 12 months) divided by reference SD for CA at 12 months Growth rate SD CA at 24 months was calculated as: (Growth rate at 24 months minus reference mean for CA at 24 months) divided by reference SD for CA at 24 months
Time frame: 12 and 24 months
Summary of Growth Rate SD (BA) at 12 Months in Children With IGF-1 < = 2 SD at 9 or 12 Months
Growth rate SD BA at 12 months was calculated as: (Growth rate at 12 months minus reference mean for BA at 12 months) divided by reference SD for BA at 12 months
Time frame: Baseline, 12 months
Summary of Growth Rate SD (BA) at 24 Months in Children With IGF-1 < = 2 SD at 9 or 12 Months
Growth rate SD BA at 24 months was calculated as: (Growth rate at 24 months minus reference mean for BA at 24 months) divided by reference SD for BA at 24 months
Time frame: Baseline, 24 months
Summary of Growth Rate SD (BA) at 12 and 24 Months in Children With IGF-1 > 2 SD at 9 and 12 Months
Growth rate SD BA at 12 months was calculated as: (Growth rate at 12 months minus reference mean for BA at 12 months) divided by reference SD for CA at 12 months Growth rate SD BA at 24 months was calculated as: (Growth rate at 24 months minus reference mean for BA at 24 months) divided by reference SD for CA at 24 months
Time frame: 12 and 24 months
Analysis of Covariance (ANCOVA) for Height SD CA at 12 Months in Children With IGF-1 < = 2 SD at 9 or 12 Months and IGF-1 > 2 SD at 9 and 12 Months
Change in Height SD (CA) was calculated as: Height SD (CA) at 12 months minus Height SD (CA) at Baseline
Time frame: Baseline, 12 months
ANCOVA for Height SD CA at 24 Months in Children With IGF-1 < = 2 SD at 9 or 12 Months and IGF-1 > 2 SD at 9 and 12 Months
Height SD (CA) at 24 months.
Time frame: Baseline, 24 months
ANCOVA for Height SD BA at 12 Months in Children With IGF-1 < = 2 SD at 9 or 12 Months and IGF-1 > 2 SD at 9 and 12 Months
Change in Height SD (BA) was calculated as: Height SD (BA) at 12 months minus Height SD (BA) at Baseline
Time frame: Baseline, 12 months
ANCOVA for Height SD BA at 24 Months in Children With IGF-1 <= 2 SD at 9 or 12 Months and IGF-1 > 2 SD at 9 and 12 Months
Height SD (BA) at 24 months
Time frame: Baseline, 24 months
Summary of IGF-1 SD at 6, 9, 12, 15, 18, 21, and 24 Months in Children With IGF-1 < = 2 SD at 9 or 12 Months
IGF-1 SD was calculated at each study time point using gender specific IGF-1 reference mean and SD for the CA of the child on the date of the corresponding IGF-1 blood sample: IGF-1 SD = (IGF-1 minus reference mean) divided by reference SD
Time frame: 6, 9, 12, 15, 18, 21, and 24 months
Summary of IGF-1 SD at 6, 9, 12, 15, 18, 21, and 24 Months in Children With IGF-1 > 2 SD at 9 and 12 Months
IGF-1 SD was calculated at each study time point using these gender specific IGF-1 reference means and SDs for the CA of the child on the date of the corresponding IGF-1 blood sample: IGF-1 SD = (IGF-1 - reference mean) / reference SD
Time frame: 6, 9, 12, 15, 18, 21, and 24 months
IGF-1/Insulin-Like Growth Factor Binding Protein 3 (IGFBP-3) Ratio at 12 and 24 Months in Children With IGF-1 < = 2 SD at 9 or 12 Months
Time frame: 12 and 24 months
IGF-1/IGFBP-3 Ratio at 12 and 24 Months in Children With IGF-1 > 2 SD at 9 and 12 Months
Time frame: 12 and 24 months
Change in Height From Baseline
The standing height measurements were performed at the same time of the day by using a wallmounted device (e.g. Harpenden Stadiometer) at each study visit. The pre-specified clinical outcomes were analyzed at 12 and 24 months.
Time frame: Baseline, 12 and 24 months
Growth Rate at 12 and 24 Months
Growth Rate was calculated at 12 months as: (Height at 12 months minus Height at Day 0) divided by {(Date of 12 months minus Date of Day 0) divided by 365.25} Growth Rate was calculated at 24 months as: (Height at 24 months minus Height at 12 months) divided by {(Date of 24 months minus Date of 12 months) divided by 365.25}
Time frame: 12 and 24 months
Summary of Body Mass Index (BMI) at 12 and 24 Months
BMI was calculated at 12 months and 24 months as: (Weight at 12 or 24 months divided by Height at 12 or 24 months) squared
Time frame: 12 and 24 months
Change in BA From Baseline at 12 and 24 Months
Change in BA was calculated as: (12 or 24 months minus Screening)
Time frame: Baseline, 12 and 24 months
BA/CA at 12 and 24 Months in Children With IGF-1 < = 2 SD at 9 or 12 Months
The BA/CA ratio was calculated at Screening, 12 and 24 months. The CA was the age on the date that the corresponding BA X-ray was performed.
Time frame: 12 and 24 months
BA/CA at 12 and 24 Months in Children With IGF-1 > 2 SD at 9 and 12 Months
The BA/CA ratio was calculated at Screening, 12 and 24 months. The CA was the age on the date that the corresponding BA X-ray was performed.
Time frame: 12 and 24 months
| Milestone | Genotonorm |
|---|---|
| Started | 57 |
| Completed | 55 |
| Not completed | 2 |
| Withdrew: Protocol violation | 2 |
The standing height measurements were performed at the same time of the day by using a wallmounted device (e.g. Harpenden Stadiometer) at each study visit. The pre-specified clinical outcomes were analyzed at 12 and 24 months.
| centimeters (cm) | Genotonorm |
|---|---|
| 12 Months | 9.0 ± 1.3 |
| 24 Months | 16.4 ± 2.2 |
Percentage of children with serum IGF-1 \> 2 SD (compared to a child of the same gender and age and without growth hormone (GH) deficiency) 9 months and 12 months after initiation of GH treatment. 9 months and 12 months are combined.
| percentage of participants | Genotonorm |
|---|---|
| No | 86.0 |
| Yes | 14.0 |
The height in SD was calculated using Sempe reference means and standard deviations for height. Change in height SD was calculated as height in SD at "12 months" minus height in SD at "Baseline".
| SD for CA | Genotonorm |
|---|---|
| Change in Height SD Chronological Age (CA) From Baseline at 12 Months in Children With IGF-1 < = 2 SD at 9 or 12 Months | 0.81 ± 0.26 |
The height in SD was calculated using Sempe reference means and SDs for height. Change in height SD was calculated as height in SD at "24 months" minus height in SD at "Baseline".
| SD for CA | Genotonorm |
|---|---|
| Change in Height SD CA From Baseline at 24 Months in Children With IGF-1 < = 2 SD at 9 or 12 Months | 1.24 ± 0.48 |
The height in SD was calculated using Sempe reference means and SDs for height. Change in height SD was calculated as height in SD at "12 or 24 months" minus height in SD at "Baseline".
| SD for BA | Genotonorm |
|---|---|
| 12 Months | 1.13 ± 0.35 |
| 24 Months | 1.53 ± 0.20 |
The height in SD was calculated using Sempe reference means and SDs for height. Change in height SD was calculated as height in SD at "12 months" minus height in SD at "Baseline".
| SD for BA | Genotonorm |
|---|---|
| Change in Height SD Bone Age (BA) From Baseline at 12 Months in Children With IGF-1 < = 2 SD at 9 or 12 Months | 0.44 ± 1.34 |
The height in SD was calculated using Sempe reference means and SDs for height. Change in height SD was calculated as height in SD at "24 months" minus height in SD at "Baseline".
| Height in SD | Genotonorm |
|---|---|
| Change in Height SD BA From Baseline at 24 Months in Children With IGF-1 < = 2 SD at 9 or 12 Months | 0.12 ± 1.86 |
The height in SD was calculated using Sempe reference means and SDs for height. Change in height SD was calculated as height in SD at "12 or 24 months" minus height in SD at "Baseline".
| SD for BA | Genotonorm |
|---|---|
| 12 Months | 0.64 ± 1.19 |
| 24 Months | 0.64 ± 1.30 |
Growth Rate was calculated at 12 months as: (Height at 12 months minus Height at Day 0) divided by {(Date of 12 months minus Date of Day 0) divided by 365.25} Growth Rate was calculated at 24 months as: (Height at 24 months minus Height at 12 months) divided by {(Date of 24 months minus Date of 12 months) divided by 365.25}
| cm/year | Genotonorm |
|---|---|
| 12 Months | 9.06 ± 1.40 |
| 24 Months (n=55) | 7.23 ± 1.38 |
Growth rate SD CA at 12 months was calculated as:(Growth rate at 12 months minus reference mean for CA at 12 months) divided by reference SD for CA at 12 months Growth rate SD CA at 24 months was calculated as:(Growth rate at 24 months minus reference mean for CA at 24 months) divided by reference SD for CA at 24 months
| SD for CA | Genotonorm |
|---|---|
| 12 Months | 3.77 ± 1.68 |
| 24 Months (n=47) | 1.74 ± 1.51 |
Growth rate SD CA at 12 months was calculated as: (Growth rate at 12 months minus reference mean for CA at 12 months) divided by reference SD for CA at 12 months Growth rate SD CA at 24 months was calculated as: (Growth rate at 24 months minus reference mean for CA at 24 months) divided by reference SD for CA at 24 months
| SD for CA | Genotonorm |
|---|---|
| 12 Months | 5.24 ± 1.64 |
| 24 Months | 2.15 ± 2.21 |
Growth rate SD BA at 12 months was calculated as: (Growth rate at 12 months minus reference mean for BA at 12 months) divided by reference SD for BA at 12 months
| SD for CA | Genotonorm |
|---|---|
| Summary of Growth Rate SD (BA) at 12 Months in Children With IGF-1 < = 2 SD at 9 or 12 Months | 2.38 ± 1.88 |
Growth rate SD BA at 24 months was calculated as: (Growth rate at 24 months minus reference mean for BA at 24 months) divided by reference SD for BA at 24 months
| SD for BA | Genotonorm |
|---|---|
| Summary of Growth Rate SD (BA) at 24 Months in Children With IGF-1 < = 2 SD at 9 or 12 Months | 1.26 ± 1.62 |
Growth rate SD BA at 12 months was calculated as: (Growth rate at 12 months minus reference mean for BA at 12 months) divided by reference SD for CA at 12 months Growth rate SD BA at 24 months was calculated as: (Growth rate at 24 months minus reference mean for BA at 24 months) divided by reference SD for CA at 24 months
| SD for BA | Genotonorm |
|---|---|
| 12 Months | 4.02 ± 2.37 |
| 24 Months (n=6) | 1.71 ± 2.26 |
BMI was calculated at 12 months and 24 months as: (Weight at 12 or 24 months divided by Height at 12 or 24 months) squared
| kg/meters squared (m2) | Genotonorm |
|---|---|
| 12 Months (n=54) | 14.7 ± 1.5 |
| 24 Months (n=55) | 14.9 ± 1.4 |
Change in Height SD (CA) was calculated as: Height SD (CA) at 12 months minus Height SD (CA) at Baseline
| SD for CA | Genotonorm (IGF-1 < = 2 SD at 9 or 12 Months) | Genotonorm (IGF-1 > 2 SD at 9 and 12 Months) |
|---|---|---|
| Analysis of Covariance (ANCOVA) for Height SD CA at 12 Months in Children With IGF-1 < = 2 SD at 9 or 12 Months and IGF-1 > 2 SD at 9 and 12 Months | -1.94 ± 0.04 | -1.59 ± 0.10 |
Height SD (CA) at 24 months.
| SD for CA | Genotonorm (IGF-1 < = 2 SD at 9 or 12 Months) | Genotonorm (IGF-1 > 2 SD at 9 and 12 Months) |
|---|---|---|
| ANCOVA for Height SD CA at 24 Months in Children With IGF-1 < = 2 SD at 9 or 12 Months and IGF-1 > 2 SD at 9 and 12 Months | -1.53 ± 0.06 | -1.18 ± 0.14 |
Change in Height SD (BA) was calculated as: Height SD (BA) at 12 months minus Height SD (BA) at Baseline
| SD for BA | Genotonorm (IGF-1 < = 2 SD at 9 or 12 Months) | Genotonorm (IGF-1 > 2 SD at 9 and 12 Months) |
|---|---|---|
| ANCOVA for Height SD BA at 12 Months in Children With IGF-1 < = 2 SD at 9 or 12 Months and IGF-1 > 2 SD at 9 and 12 Months | 0.56 ± 0.22 | 0.76 ± 0.48 |
Height SD (BA) at 24 months
| SD for BA | Genotonorm (IGF-1 < = 2 SD at 9 or 12 Months) | Genotonorm (IGF-1 > 2 SD at 9 and 12 Months) |
|---|---|---|
| ANCOVA for Height SD BA at 24 Months in Children With IGF-1 <= 2 SD at 9 or 12 Months and IGF-1 > 2 SD at 9 and 12 Months | 0.05 ± 0.25 | 0.64 ± 0.53 |
Change in BA was calculated as: (12 or 24 months minus Screening)
| year | Genotonorm |
|---|---|
| 12 Months (n=33) | 1.2 ± 0.9 |
| 24 Months (n=31) | 2.5 ± 1.1 |
The BA/CA ratio was calculated at Screening, 12 and 24 months. The CA was the age on the date that the corresponding BA X-ray was performed.
| ratio | Genotonorm |
|---|---|
| 12 Months | 0.74 ± 0.17 |
| 24 Months | 0.82 ± 0.16 |
The BA/CA ratio was calculated at Screening, 12 and 24 months. The CA was the age on the date that the corresponding BA X-ray was performed.
| ratio | Genotonorm |
|---|---|
| 12 Months | 0.80 ± 0.21 |
| 24 Months | 0.83 ± 0.09 |
IGF-1 SD was calculated at each study time point using gender specific IGF-1 reference mean and SD for the CA of the child on the date of the corresponding IGF-1 blood sample: IGF-1 SD = (IGF-1 minus reference mean) divided by reference SD
| SD | Genotonorm |
|---|---|
| 6 Months (n=49) | 0.65 ± 1.11 |
| 9 Months (n=46) | 0.93 ± 1.26 |
| 12 Months (n=44) | 1.04 ± 0.96 |
| 15 Months (n=40) | 0.88 ± 1.28 |
| 18 Months (n=43) | 0.88 ± 1.17 |
| 21 Months (n=41) | 0.82 ± 0.93 |
| 24 Months (n=45) | 0.85 ± 1.17 |
IGF-1 SD was calculated at each study time point using these gender specific IGF-1 reference means and SDs for the CA of the child on the date of the corresponding IGF-1 blood sample: IGF-1 SD = (IGF-1 - reference mean) / reference SD
| SD | Genotonorm |
|---|---|
| 6 Months (n=7) | 2.32 ± 0.68 |
| 9 Months (n=6) | 2.35 ± 0.19 |
| 12 Months (n=8) | 2.50 ± 0.27 |
| 15 Months (n=7) | 1.40 ± 1.08 |
| 18 Months (n=7) | 2.12 ± 1.18 |
| 21 Months (n=7) | 1.82 ± 1.09 |
| 24 Months (n=8) | 1.81 ± 1.03 |
| ratio | Genotonorm |
|---|---|
| 12 Months (n=44) | 0.17 ± 0.06 |
| 24 Months (n=45) | 0.19 ± 0.07 |
| ratio | Genotonorm |
|---|---|
| 12 Months | 0.23 ± 0.03 |
| 24 Months | 0.21 ± 0.06 |
Non-serious events are listed at a 0% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Genotonorm | — | 6/57 (10.5%) | 30/57 (52.6%) |
| Event | Genotonorm |
|---|---|
| Amniotic band syndromeCongenital, familial and genetic disorders | 1/57 |
| DeafnessEar and labyrinth disorders | 1/57 |
| PneumoniaInfections and infestations | 1/57 |
| Staphylococcal infectionInfections and infestations | 1/57 |
| DysuriaRenal and urinary disorders | 1/57 |
| HaematuriaRenal and urinary disorders | 1/57 |
| PleurisyRespiratory, thoracic and mediastinal disorders | 1/57 |
| Tonsillar hypertrophyRespiratory, thoracic and mediastinal disorders | 1/57 |
| Event | Genotonorm |
|---|---|
| VaricellaInfections and infestations | 6/57 |
| BronchitisInfections and infestations | 5/57 |
| HeadacheNervous system disorders | 5/57 |
| ConstipationGastrointestinal disorders | 4/57 |
| NasopharyngitisInfections and infestations | 4/57 |
| RhinitisInfections and infestations | 4/57 |
| Ear infectionInfections and infestations | 3/57 |
| GastroenteritisInfections and infestations | 3/57 |
| Insulin-like growth factor increasedInvestigations | 3/57 |
| CoughRespiratory, thoracic and mediastinal disorders | 3/57 |
| Age, Customized(participants) | Genotonorm |
|---|---|
| <4 years | 1 |
| Between 4 and 8 years | 49 |
| Between 8 and 12 years | 7 |
| >=12 years | 0 |
| Sex: Female, Male(Participants) | Genotonorm |
|---|---|
| Female | 34 |
| Male | 23 |
The record gives a start of Feb 2005, a primary completion of Apr 2009 and a completion of Apr 2009. It does not say whether these dates are actual or estimated.
Results were first posted in Jun 2010, 1 year 2 months after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Jun 2009. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Human Growth Hormone